U.S.
SECURITIES AND EXCHANGE COMMISSION
 Washington,
D.C. 20549
 Form
10-Q


Mark
      One
                      [
      X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES
                      EXCHANGE
      ACT OF 1934
                      
                      For
      the period ended March 31, 2009
                      
                      [   ]  TRANSITION
      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                      EXCHANGE
      ACT OF 1934
                      
                      For
      the transition period from ______ to _______
  Commission
File No. 000-52703
 
 Kinder Travel, Inc.
                                (Name
      of small business issuer in its charter)Nevada
                                (State
      or other jurisdiction of incorporation
                                or
      organization)
                              20-4939361
                                (I.R.S.
      Employer Identification No.)1461 A. First Avenue, Suite 360
      New York, NY(Address
      of principal executive offices)(646)845-1920
                                (Issuer’s
      telephone number)Securities
      registered pursuant to Section
                                12(b)
      of the Act:
                              Name
      of each exchange on which
                                registered:NoneSecurities
      registered pursuant to Section 12(g) of the Act:Common Stock,
      $0.001(Title
      of
Class)
  Indicate
by checkmark whether the issuer: (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes [X
]   No [    ]
  Table
of Contents
 1
 Indicate
by check mark whether the registrant is a large accelerated filed, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company.
  Large accelerated
      filer [  ]
              Accelerated filer
      [   ]Non-accelerated
      filer [   ]
              Smaller reporting
      company [X]
  Indicate
by checkmark whether the registrant is a shell company (as defined in Rule 12b-2
of the Exchange Act). Yes [   ]  No [X]
   Applicable
Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five
Years. N/A
  Indicate
by checkmark whether the issuer has filed all documents and reports required to
be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934
after the distribution of securities under a plan confirmed by a
court.  Yes[   ]  No[   ]
  Applicable
Only to Corporate Registrants
  Indicate
the number of shares outstanding of each of the issuer’s classes of common
stock, as of the most practicable date:
  Class
              Outstanding
      as of  May 4, 2009Common
      Stock, $0.001
              2,650,000
  Table
of Contents
 2
 
 KINDER
TRAVEL, INC.
 
 Form
10-Q
 
 Part
      1.
                    FINANCIAL
      INFORMATION
                    PageItem 1.
                    Unaudited Financial
    StatementsBalance
      Sheets
                    4Statements
      of Operations
                    5Statements
      of Cash Flows
                    6Notes
      to Financial Statements
                    7Item 2.
                    Management’s
      Discussion and Analysis of Financial Condition and Results of
      Operations
                    8Item 3.
                    Quantitative
      and Qualitative Disclosures About Market Risk
                    15Item 4.
                    Controls
      and Procedures
                    15Part
      II.
                    OTHER
      INFORMATIONItem 1.
                    Legal
      Proceedings
                    16Item 1A.
                    Risk
      Factors
                    16Item 2.
                    Unregistered
      Sales of Equity Securities and Use of Proceeds
                    16Item 3.
                    Defaults
      Upon Senior Securities
                    17Item 4.
                    Submission
      of Matters to a Vote of Security Holders
                    17Item 5.
                    Other
      Information
                    17Item 6.
                    Exhibits
                    19
 
 Table
of Contents
 3
 PART
I
 
 ITEM1. FINANCIAL STATEMENTS
 
 Kinder
      Travel, Inc.Balance
      Sheets(In
      Canadian Dollars)(Unaudited)March
      31, 2009
                
                
                December
      31, 2008ASSETSCurrent
      AssetsCash
                
                $
                19,451
                
                
                $
                21,220Accounts
      receivable, net
                
                
                11,329
                
                
                
                -Prepaid
      expenses
                
                
                5,644
                
                
                
                -Total
      Current Assets
                
                
                36,424
                
                
                
                21,220Other
      AssetsVehicles
      and equipment, net of accumulated depreciation
                
                
                19,212
                
                
                
                21,957Website,
      net of accumulated amortization
                
                
                1,185
                
                
                
                1,777Travel
      agency bond
                
                
                15,000
                
                
                
                15,000Total
      Other Assets
                
                
                35,397
                
                
                
                38,734TOTAL
      ASSETS
                
                $
                71,821
                
                
                $
                59,954LIABILITIESCurrent
      LiabilitiesAccounts
      payable
                
                $
                42,785
                
                
                $
                37,157Accrued
      liabilities
                
                
                3,711
                
                
                
                4,286Payroll
      liabilities
                
                
                2,532
                
                
                
                2,085Sales
      tax payable
                
                
                445
                
                
                
                105Customer
      prepayments
                
                
                -
                
                
                
                310Shareholders'
      loans
                
                
                35,143
                
                
                
                31,273Current
      portion of long-term debt
                
                
                1,159
                
                
                
                1,136Total
      Current Liabilities
                
                
                85,775
                
                
                
                76,352Long
      Term LiabilitiesLoan
      payable
                
                
                18,983
                
                
                
                19,282Total
      Long Term Liabilities
                
                
                18,983
                
                
                
                19,282TOTAL
      LIABILITIES
                
                
                104,758
                
                
                
                95,634STOCKHOLDERS’
      DEFICITCapital
      StockPreferred
      StockAuthorized:  10,000,000
      shares with $0.001 par value. Issued: 0
                
                
                -
                
                
                
                -Common
      StockAuthorized:
      65,000,000 common shares with $0.001 par valueIssued:  2,400,000
                
                
                2,691
                
                
                
                2,691Additional
      paid-in capital
                
                
                130,764
                
                
                
                130,109Accumulated
      other comprehensive income
                
                
                (759
                )
                
                
                (855
                )Retained
      Earnings
                
                
                (165,633
                )
                
                
                (167,625
                )TOTAL
      STOCKHOLDERS' DEFICIT
                
                
                (32,937
                )
                
                
                (35,680
                )TOTAL
      LIABILITIES AND STOCKHOLDERS' DEFICIT
                
                $
                71,821
                
                
                $
                59,954The
      accompanying notes are an integral part of these consolidated financials
      statements.
 
  Table
of Contents
 4
  
 Kinder
      Travel, Inc.Statements
      of Operations(In
      Canadian Dollars)(Unaudited)For
      the Three
                    
                    For
      the ThreeMonths
      Ended
                    
                    Months
      EndedMarch
      31, 2009
                    
                    March
      31, 2008Sales
                    
                    $
                    66,849
                    
                    $
                    71,545Cost
      of Sales
                    
                    
                    32,966
                    
                    
                    14,701Gross
      Margin
                    
                    
                    33,883
                    
                    
                    56,844General
      and Administrative ExpensesAutomobile
      Expense
                    
                    
                    3,881
                    
                    
                    3,349Depreciation
      and Amortization
                    
                    
                    3,337
                    
                    
                    2,387General
      and Administrative
                    
                    
                    7,052
                    
                    
                    17,094Payroll
      Expenses
                    
                    
                    12,945
                    
                    
                    24,692Professional
      Fees
                    
                    
                    4,676
                    
                    
                    7,322Total
      Expenses
                    
                    
                    31,891
                    
                    
                    54,844Income
      from Operations
                    
                    
                    1,992
                    
                    
                    2,000Provision
      for Income Tax
                    
                    
                    -
                    
                    
                    -Net
      Income
                    
                    $
                    1,992
                    
                    $
                    2,000Comprehensive
      IncomeNet
      Income
                    
                    
                    1,992
                    
                    
                    2,000Foreign
      currency translation adjustment
                    
                    
                    96
                    
                    
                    204Total
      Comprehensive Income
                    
                    $
                    2,088
                    
                    $
                    2,204$
                    0.00
                    
                    $
                    0.00Income
      per Share – Basic and Diluted2,400,000
                    
                    
                    2,400,000Weighted
      Average Shares OutstandingThe
      accompanying notes are an integral part of these consolidated financials
      statements.
 
  Table
of Contents
 5
  Kinder
      Travel, Inc.Statements
      of Cash Flows(In
      Canadian Dollars)(Unaudited)For
      the Three Months Ended
                  March
      31, 2009
                
                
                For
      the Three Months Ended
                  March
      31, 2008Operating
      ActivitiesNet
      Income
                
                $
                1,992
                
                
                $
                2,000Adjustments
      to reconcile net income to net cash flows used in operating
      activitiesDepreciation
      and Amortization
                
                
                3,337
                
                
                
                12,561Imputed
      interest of shareholders loans
                
                
                655
                
                
                
                -Changes
      in operating assets and liabilitiesAccounts
      receivable
                
                
                (11,329
                )
                
                
                401Prepaid
      Expenses
                
                
                (5,644
                )
                
                
                (4,464
                )Accounts
      payable
                
                
                5,628
                
                
                
                8,381Accrued
      liabilities
                
                
                (575
                )
                
                
                4,446Payroll
      Liabilities
                
                
                447
                
                
                
                (26,558
                )Sales
      Tax Payable
                
                
                340
                
                
                
                1,068Customer
      Prepayments
                
                
                (310
                )
                
                
                (5,493
                )Net
      cash flows used in operations
                
                $
                (5,459
                )
                
                $
                (7,657
                )Financing
      ActivitiesBorrowings
      on debt
                
                
                13,291
                
                
                
                -Payments
      on debt
                
                
                (9,697
                )
                
                
                5,506Net
      cash flows provided by financing activities
                
                $
                3,594
                
                
                $
                5,506Effect
      of exchange rate changes
                
                
                96
                
                
                
                204Change
      in Cash
                
                
                (1,769
                )
                
                
                (1,948
                )Cash
      - Beginning
                
                
                21,220
                
                
                
                26,824Cash
      – Ending
                
                $
                19,451
                
                
                $
                24,876Supplemental
      Cash Flow InformationCash
      paid for:Income
      Taxes
                
                $
                -
                
                
                $
                -Interest
                
                $
                -
                
                
                $
                -The
      accompanying notes are an integral part of these consolidated financials
      statements.
 
  Table
of Contents
 6
 KINDER
TRAVEL, INC.
 
 NOTES
TO UNAUDITED FINANCIAL STATEMENTS
 
 MARCH
31, 2009
 (In
Canadian Dollars)
 
 
 Note
1 – Basis of Presentation
 
 The
accompanying unaudited interim consolidated financial statements of Kinder
Travel, Inc. have been prepared in accordance with accounting principles
generally accepted in the United States of America and the rules of the
Securities and Exchange Commission, and should be read in conjunction with
Kinder's audited 2008 annual financial statements and notes thereto filed with
the SEC on form 10-K. In the opinion of management, all adjustments, consisting
of normal recurring adjustments, necessary for a fair presentation of financial
position and the result of operations for the interim periods presented have
been reflected herein. The results of operations for interim periods are not
necessarily indicative of the results to be expected for the full year. Notes to
the financial statements, which would substantially duplicate the disclosure
required in Kinder's 2008 annual financial statements have been
omitted.
 
 Note
2 - Going Concern
 
 Kinder's
financial statements have been prepared on a going concern basis, which
contemplates the realization of assets and settlement of liabilities and
commitments in the normal course of business for the foreseeable future. Since
inception, the Company has accumulated losses aggregating to $165,633 and has
insufficient working capital to meet operating needs for the next twelve months
as of March 31, 2009, all of which raise substantial doubt about the Company’s
ability to continue as a going concern.
 
 Note
3 – Shareholder Loans
 
 As of
March 31, 2009 and December 31, 2008, the total due to shareholders was $35,143
and $31,273, respectively. These loans are unsecured, non-interest bearing, and
have no specific repayment terms. Imputed interest of $655 was calculated at a
rate of 8% and recorded in additional paid-in capital at March 31,
2009
 
 Note
4 – Related Party Transactions
 
 There
were no related party transactions other than the shareholder loans as described
in Note 3.
 
 Note
5 - Subsequent Events
 
 1.
              On
      April  20, 2009, the Company issued 250,000 common shares at
      $0.30 per share for the purchase of the rights and title to 3 medical
      patents pursuant to an asset purchase agreement dated April 15,
      2009;
 2.
              On
      April 20, 2009, the Board of Directors approved a forward stock split of
      125 new shares for each old share to be effective approximately May 31,
      2009. These financials statements do not reflect the effects of the
      forward stock split.
 3.
              On
      April 20, 2009, our Board of Directors approved the execution of an asset
      purchase agreement with Dirk Holzhauer (“Holzhauer”), one of our
      shareholders, a director, and a former officer. In accordance with the
      provisions of the Agreement, we will sell the assets of the Company,
      including the intangible assets related to the travel business, to
      Holzhauer for a purchase price of $57,489 and as payment Holzhauer shall
      return to us an aggregate of 191,631 shares of our common stock. The
      Agreement is subject to shareholder approval and its effects are not
      reflected in these financials
statements.
 4.
              On
      April 24, 2009, an amendment was filed with the State of Nevada to change
      the name of the Company to Genova Biotherapeutics,
  Inc.
 5.
              On
      April 24, 2009, an amendment was filed with the State of Nevada to
      increase the authorized share capital of the company from 65,000,000
      shares, par value of $0.001, to 1,000,000,000 shares, par value $0.00001.
      These financials statements do not reflect the effects of the change of
      share capital or par value.
  Table
of Contents
 7
 FORWARD
LOOKING STATEMENTS
 
 Statements
made in this Form 10-Q that are not historical or current facts are
"forward-looking statements" made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933 (the "Act") and Section 21E of the
Securities Exchange Act of 1934. These statements often can be identified by the
use of terms such as "may," "will," "expect," "believe," "anticipate,"
"estimate," "approximate" or "continue," or the negative thereof. We intend that
such forward-looking statements be subject to the safe harbors for such
statements. We wish to caution readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made. Any
forward-looking statements represent management's best judgment as to what may
occur in the future. However, forward-looking statements are subject to risks,
uncertainties and important factors beyond our control that could cause actual
results and events to differ materially from historical results of operations
and events and those presently anticipated or projected. We disclaim any
obligation subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statement or to reflect the
occurrence of anticipated or unanticipated events.
 
 ITEM
2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
 
 GENERAL
 
 Kinder
Travel, Inc. is a corporation organized under the laws of the State of Nevada in
December 2005. Initial operations commenced under the name “Kinder Travel &
Tours” as a sole proprietorship in January 2005. In November 2005, Kinder Travel
& Tours was incorporated under the laws of the Province of British Columbia
as Kinder Travel, Inc. (“KTBC”). On December 6, 2005, Kinder Travel, Inc. was
incorporated under the laws of the State of Nevada. Subsequently, pursuant to
the terms and provisions of an asset purchase agreement (the “Asset Purchase
Agreement”) with KTBC, we acquired all of the assets and liabilities of KTBC in
exchange for a convertible note of $20,000 (the “Note”). The Note was
subsequently distributed to KTBC’s sole shareholder, Dirk Holzhauer, who
converted the Note into 400,000 shares of our restricted common stock. After the
effective date of our registration statement filed with the Securities and
Exchange Commission (February 2, 2007), we commenced trading on the
Over-the-Counter Bulletin Board under the symbol “KNDT:OB” on approximately July
3, 2007.
 
 From
inception, we have been a travel agency offering a full range of travel services
including corporate travel, vacations, cruise holidays, and group tours. Our
primary focus was selling, marketing and providing travel services and tours to
families, businesses and ministries. Our focus was to provide travel that
promoted family values via our website. Our website consisted of an on-line
booking engine geared to providing Christian families with travel options that
promoted unity. The full-scale version of our website was launched in October
2006.
 
 Please
note that throughout this Quarterly Report, and unless otherwise noted, the
words "we," "our," "us," the "Company," or "Kinder Travel," refers to Kinder
Travel, Inc.
  Table
of Contents
 8
 RECENT
CORPORATE DEVELOPMENTS
 
 Change
in Corporate Name
 
 In
accordance with the decision by our Board of Directors to effectuate a change in
the nature of our business operations as described below, our Board of Directors
has determined that it may be in our best interests and our shareholders to seek
approval for change in our corporate name and a corresponding amendment to the
articles of corporation to “Genova Biotherapeutics Inc.” (the “Name
Change”).
 
 The
objective of the change in our corporate name is deemed necessary to more
accurately reflect our proposed business activities in our name. We believe that
the Name Change will better communicate to the public our proposed and future
nature of business operations.
 
 The Board
of Directors approved a resolution on April 20, 2009 to amend our Articles of
Incorporation in accordance with the Name Change, subject to shareholder
approval pursuant to written consent by shareholders. By approving this
proposal, the shareholders will authorize our Board of Directors to amend our
Articles of Incorporation to “Genova Biotherapeutics Inc.”.  After the
Name Change it is anticipated that our trading symbol for the OTC Bulletin
Board will be changed. See “Part II. Item 4. Submission of Matters to a
Vote of Security Holders.”
 
 Increase
in Authorized Capital Structure
 
 In
accordance with the decision by our Board of Directors to effectuate a change in
the nature of the Corporation’s business operations as described below, our
Board of Directors has determined that it is in our best interests and our
shareholders to increase our authorized capital structure from 65,000,000 shares
of common stock with a par value of $0.001 to 1,000,000,000 shares of common
stock with a par value of $0.00001 per share (the “Change in Capital Structure
Amendment”)
 
 The
objective of the Change in Capital Structure Amendment is to allow for future
issuances of our common stock in accordance with forward stock splits, proposed
equity financings, debt settlement, and contractual provisions. Our Board of
Directors believes that an increase in the authorized capital structure will
increase our marketability and liquidity in the future.
 
 The Board
of Directors approved a resolution on April 20, 2009 to amend our Articles of
Incorporation in accordance with the Change in Capital Structure Amendment,
subject to shareholder approval pursuant to written consent by shareholders. By
approving this proposal, the shareholders will authorize our Board of Directors
to amend our Articles of Incorporation to increase our authorized capital
structure from 65,000,000 shares of common stock, par value $0.001 to
1,000,000,000 shares of common stock, par value $0.00001. See “Part II. Item 4.
Submission of Matters to a Vote of Security Holders.”
 
 As of the
date of this Quarterly Report, we have filed the amendment with the Nevada
Secretary of State regarding the Name Change and the Change in Capital
Structure.
  Table
of Contents
 9
 CURRENT
BUSINESS OPERATIONS
 
 Our Board
of Directors has been engaged in an analysis of the current travel industry
including, but not limited to: (i) general economic conditions relating to
travel; (ii) current appeal of websites to businesses and travelers to purchase
significantly more travel products online than previously; (iii) growth of the
usage of the Internet as a medium of commerce for travel products; and (iv)
current travel industry competition. Our Board of Directors determined that we
may not grow as a business as expected. The success of our business was
dependent on a significant increase in the number of consumers who use the
Internet to purchase travel products. In order to increase the number of
consumer transactions, we needed to attract more visitors to our website and
covert a larger number of these visitors into paying customers. Our Board of
Directors further determined that our success in attracting a significant number
of business travelers to use our services was not certain based on an analysis
of the above factors. We could not be assured that our marketing and advertising
efforts would be effective to attract new customers. If we failed to attract
customers and increase our overall number of consumer transactions in a
cost-effective manner, our ability to grow and become profitable would have been
greatly impaired.
 
 Therefore,
our Board of Directors has been engaged in discussions and negotiations
regarding a change in our strategic business operational planning. These
discussions lead to a decision by our Board of Directors to divest and sell our
travel related products and assets and acquire the right, title and interest in
and to three separate medical patents as described below.
 
 Asset
Purchase Agreement
 
 As
discussed above, our Board of Directors has been engaged in discussions
regarding strategic business operational planning. In furtherance of this
strategic planning, our Board of Directors has been engaged in negotiations
regarding a transaction in which we would acquire the right, title and interest
in and to three separate medical patents (collectively, the “Medical Patents”),
owned by Phoinos Oxford Lifesciences Limited, a company incorporated under the
laws of the Federation of St. Kitts & Nevis (the “Seller”)the Seller
(collectively, the “Medical Patents”).
  Effective
on April 15, 2009, our Board of Directors approved the execution of an asset
purchase agreement dated April 15, 2009 (the “Asset Purchase Agreement”) with
the Seller. In accordance with the terms and provisions of the Asset Purchase
Agreement: (i) we will purchase the right, title and interest in and to the
Medical Patents for $75,000.00 (the “Purchase Price”); (ii) as payment of the
Purchase Price for the Medical Patents, we shall issue to the Seller an
aggregate of 250,000 shares of our restricted common stock valued at
$0.30  per share. The Asset Purchase Agreement was subject to due
diligence by us and the Seller.
  On April
20, 2009, our due diligence was completed to the satisfaction of both parties
and the Asset Purchase Agreement was consummated. Therefore, on April 20, 2009,
the right, title and interest to the Medical Patents were transferred by the
Seller to us and we issued the 250,000 shares of our restricted stock to the
Seller as consideration for the Medical Patents. See “Part II. Item 2.
Unregistered Sales of Securities and Use of Proceeds.”
  Table
of Contents
 10
 The
Agreement
 
 As
discussed above, our Board of Directors has been further engaged in discussions
and negotiations regarding strategic business operational planning pertaining to
a divesture and sale of our travel related products and assets including, but
not limited to, suppliers list, customer and vendor lists, records, trade name,
trademark and trade secrets, trade practices, goodwill, clients, equipment,
furniture, machinery, fixtures, supplies, inventory, existing contract and
tangible personal property (the “Assets”). Our Board of Directors furthermore
has engaged in several analysis regarding the fair market value of our Assets
based primarily upon a consideration of two valuations of a business using the
tangible asset valuation method and the industry multiplier valuation method in
connection with the offer and sale of our Assets, and determined that the Board
of Directors should be authorized to divest us of our travel business and
related Assets at a price not less than the midpoint of those two valuation
methods. Our Board of Directors determined that our Assets are to be valued at
$57,489.
  Effective
on April 20, 2009, our Board of Directors approved the execution of an asset
purchase agreement dated April 20, 2009 (the “Agreement”) with Dirk Holzhauer,
one of our shareholders, a director, and a former officer (the “Purchaser”). In
accordance with the terms and provisions of the Agreement: (i) we will sell to
the Purchaser the Assets for a purchase price of $57,489 (the “Purchase Price”);
and (ii) as payment for the Assets, the Purchaser shall return to us an
aggregate of 191,631 shares of our common stock held of record by the Purchaser
valued at $0.30 per share based upon the average of the open and close bid of
$0.30 of our shares of common  stock as traded on the OTC Bulletin
Board as of October 8, 2008.
  The Asset
Purchase Agreement is subject to due diligence to be conducted by the parties.
The consummation of the Agreement is subject to shareholder approval. See “Part
II. Item The Purchaser, Dirk Holzhauer, has agreed to abstain from the
vote.
  As of the
date of this Quarterly Report, we anticipate the closing of the transaction no
later than May 31, 2009.
   Table
of Contents
 11
 We have
incurred recurring losses to date. Our financial statements have been prepared
assuming that we will continue as a going concern and, accordingly, do not
include adjustments relating to the recoverability and realization of assets and
classification of liabilities that might be necessary should we be unable to
continue in operation.
 
 We expect
we will require additional capital to meet our long term operating requirements.
We expect to raise additional capital through, among other things, the sale of
equity or debt securities.
 
 Three
Month Period Ended March 31, 2009 Compared to Three Month Period Ended March 31,
2008.
 
 Our
comprehensive income during the three month period ended March 31, 2009 was
$2,088 compared to a comprehensive income of $2,206 during the three month
period ended March 31, 2008 (a slight decrease of $118). During the three month
periods ended March 31, 2009 and 2008, we generated gross sales income of
$66,849 and $71,545, respectively. Cost of sales increased during the three
month period ended March 31, 2009 to $32,966 from $14,701 during the three month
period ended March 31, 2008, resulting in net sales, or a gross margin, of
$33,883 for the three month period ended March 31, 2009  compared to
$56,845 for the same period in 2008.
 
 During
the three month period ended March 31, 2009, we incurred general and
administrative expenses of approximately $31,891 compared to $54,843 incurred
during the three month period ended March 31, 2008 (a decrease of $22,952).
These general and administrative expenses incurred during the three month period
ended March 31, 2009 consisted of: (i) automobile expenses of $3,881 (2008:
$3,349); (ii) depreciation and amortization of $3,337 (2008: $2,387); (iii)
general and administrative of $7,052 (2008: $17,094); (iv) payroll expenses of
$12,945 (2008: $24,692); and (v) professional fees of $4,675 (2008:
$7,322).
 
 General
and administrative expenses incurred during the three month period ended March
31, 2009 compared to the three month period ended March 31, 2008 decreased
primarily due to the decrease in expenses associated with payroll and general
and administrative. General and administrative expenses generally include
corporate overhead, financial and administrative contracted services, marketing,
and consulting costs.
 
 Foreign
currency translation adjustment costs incurred during the three month periods
ended March 31, 2009 and March 31, 2008 were $96 and $204 respectively. This
resulted in a comprehensive income of $2,088 or ($0.0) per share for the three
month period ended March 31, 2009 compared to a comprehensive income of $2,206
or ($0.00) per share for the three month period ended March 31, 2008. The
weighted average number of shares outstanding was 2,400,000 for the three month
periods ended March 31, 2009 and March 31, 2008.
 
 Table
of Contents
 12
 LIQUIDITY
AND CAPITAL RESOURCES
 
 As
of March 31, 2009
 
 As at the
three month period ended March 31, 2009, our current assets were $36,424 and our
current liabilities were $85,774, which resulted in a working capital deficiency
of ($49,350). As at the three month period ended March 31, 2009, current assets
were comprised of: (i) $19,451 in cash; (ii) $11,329 in accounts receivable (net
of allowance for doubtful accounts); and (iii) $5,644 in prepaid expenses. As at
the three month period ended March 31, 2009, current liabilities were comprised
of: (i) $42,785 in accounts payable; (ii) $3,711 in accrued liabilities; (iii)
$2,532 in payroll liabilities; (iv) $444 in sales tax payable; (v) $35,143 in
shareholders’ loan; and (vi) $1,159 in current portion of long-term
debt.
 
 As at the
three month period ended March 31, 2009, our total assets were $71,821 comprised
of: (i) $36,424 in current assets; (ii) $19,212 in vehicles and equipment (net
of accumulated depreciation); (iii) $1,185 in website (net of accumulated
amortization); and (iv) $15,000 in travel agency bond. The slight increase in
total assets during the three month period ended March 31, 2009 from fiscal year
ended December 31, 2008 was primarily due to the increase in accounts receivable
and prepaid expenses.
 
 As at the
three month period ended March 31, 2009, our total liabilities were $104,758
comprised of: (i) $85,774 in current liabilities; and (ii) $18,983 in loan
payable. The increase in liabilities during the three month period ended March
31, 2009 from fiscal year ended December 31, 2008 was primarily due to an
increase in accounts payable and shareholders’ loan. See “ – Material
Commitments”.
 
 Stockholders’
deficit decreased from ($35,680) for fiscal year ended December 31, 2008 to
stockholders’ deficit of ($32,937) for the three month period ended March 31,
2009.
 
 Cash
Flows from Operating Activities
 
 We have
not generated positive cash flows from operating activities. For the three month
period ended March 31, 2009, net cash flows used in operating activities was
($5,459), consisting primarily of net income of $1,992. Net cash flows used in
operating activities was adjusted by $3,338 for depreciation and amortization
and $655 in imputed interest of shareholders loans. Net cash flows used in
operating activities was further changed by: (i) accounts receivable of
($11,329); (ii) prepaid expenses of ($5,644); (iii) accounts payable of $5,628;
(iv) accrued liabilities of ($575); (v) payroll liabilities of $447; (vi) sales
tax payable of $338; and (vii) customer prepayments of ($310).  For
the three month period ended March 31, 2008, net cash flows used in operating
activities was ($7,656), consisting primarily of net income of $2,001, adjusted
by $12,501 in depreciation and amortization. Net cash flows used in operating
activities was further changed by: (i) accounts receivable of $401; (ii) prepaid
expenses of ($4,464); (iii) accounts payable of $8,381; (iv) accrued liabilities
of $4,446; (v) payroll liabilities of ($26,558); (vi) sales tax payable of
$1,068; and (vii) customer prepayments of ($5,493).
 
 Cash
Flows from Investing Activities
 
 For the
three month periods ended March 31, 2009 and March 31, 2008, net cash flows used
in investing activities was $-0-.
 
 Table
of Contents
 13
 Cash
Flows from Financing Activities
 
 We have
financed our operations primarily from either advancements or the issuance of
equity and debt instruments. For the three month period ended March 31, 2009,
net cash flows provided from financing activities was $3,594 compared to
($5,506) for the three month period ended March 31, 2008. Cash flows from
financing activities for the three month period ended March 31, 2009 consisted
of $13,291 in borrowings on debt offset by ($9,696) in payments on debt. Cash
flows from financing activities for the three month period ended March 31, 2008
consisted of ($5,506) in payments on debt.
 
 We expect
that working capital requirements will continue to be funded through a
combination of our existing funds and further issuances of securities. Our
working capital requirements are expected to increase in line with the growth of
our business.
 
 PLAN
OF OPERATION AND FUNDING
 
 Existing
working capital, further advances and debt instruments, and anticipated cash
flow are expected to be adequate to fund our operations over the next six
months. We have no lines of credit or other bank financing arrangements.
Generally, we have financed operations to date through the proceeds of the
private placement of equity and debt instruments. In connection with our
business plan, management anticipates additional increases in operating expenses
and capital expenditures relating to the development, marketing and distribution
of products relating to the Medical Patents. We intend to finance these expenses
with further issuances of securities, and debt issuances. Thereafter, we expect
we will need to raise additional capital and generate revenues to meet long-term
operating requirements. Additional issuances of equity or convertible debt
securities will result in dilution to our current shareholders. Further, such
securities might have rights, preferences or privileges senior to our common
stock. Additional financing may not be available upon acceptable terms, or at
all. If adequate funds are not available or are not available on acceptable
terms, we may not be able to take advantage of prospective new business
endeavors or opportunities, which could significantly and materially restrict
our business operations.
 
 MATERIAL
COMMITMENTS
 
 As of
March 31, 2009, the total due to shareholders was $35,143. These loans are
unsecured, non-interest beading and have no specific repayment terms. Imputed
interest of $655 was calculated at a rate of 7.89% and recorded in additional
paid-in capital at March 31, 2009.
 
 PURCHASE
OF SIGNIFICANT EQUIPMENT
 
 We do not
intend to purchase any significant equipment during the next twelve
months.
 
 OFF-BALANCE
SHEET ARRANGEMENTS
 
 As of the
date of this Quarterly Report, we do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that
are material to investors.
 
 Table
of Contents
 14
 GOING
CONCERN
 
 The
independent auditors' report accompanying our December 31, 2008 and December 31,
2007 financial statements contains an explanatory paragraph expressing
substantial doubt about our ability to continue as a going concern. The
financial statements have been prepared "assuming that we will continue as a
going concern," which contemplates that we will realize our assets and satisfy
our liabilities and commitments in the ordinary course of business.
 
 ITEM
III. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.
  Market
risk represents the risk of loss that may impact our financial position, results
of operations or cash flows due to adverse change in foreign currency and
interest rates.
 Exchange
Rate
  Our
reporting currency is the Canadian Dollar. In the event we engage in business
operations within the United States and outside of Canada, the fluctuation of
exchange rates may have positive or negative impacts on our results of
operations. However, since our business operations are primarily contemplated to
occur within Canada, any potential revenue and expenses will be denominated in
Canadian Dollar, and the net income effect of appreciation and devaluation of
the currency against the Canadian would be limited to our costs of engaging in
business operations outside of Canada.
  Interest
Rate
  Interest
rates in Canada are generally controlled. Any potential future loans will relate
mainly to the development and marketing of our Medical Patents and will be
mainly short-term. However our debt may be likely to rise in connection
with expansion of operations and if interest rates were to rise at the same
time, this could become a significant impact on our operating and financing
activities. We have not entered into derivative contracts either to hedge
existing risks of for speculative purposes.
  ITEM IV. CONTROLS AND PROCEDURES
  We  carried
out an evaluation, under the supervision and with the
participation   of  our  management,  including   our   principal
executive  officer  and  principal  financial  officer,  of   the
effectiveness  of  our  disclosure
controls  and  procedures  (as
defined  in  Rules  13a-15(e) and 15d-15(e) of
the  Exchange  Act
(defined  below)).   Based  upon that
evaluation,  our  principal executive officer and principal
financial officer concluded that,
as  of  the  end  of  the  period
covered  in  this  report,  our
disclosure controls and procedures were effective to ensure  that
information required to be disclosed in reports
filed  under  the Securities Exchange Act of 1934, as
amended (the "Exchange  Act")
is  recorded,  processed,  summarized  and  reported  within  the
required time periods and is accumulated and communicated to  our
management,   including  our  principal  executive  officer   and
principal  financial  officer,
as  appropriate  to  allow  timely
decisions regarding required disclosure.
  Table
of Contents
 15
 Our
management, including our principal executive officer and principal financial
officer, does not expect that our disclosure controls and procedures or our
internal controls will prevent all error or fraud.  A control system,
no matter how well conceived
and   operated,  can  provide  only  reasonable,  not   absolute,
assurance   that  the  objectives  of  the  control  system   are
met.   Further, the design of a control system must reflect the
fact that there are resource constraints and the benefits of controls must be
considered relative to their costs.  Due to the inherent limitations
in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, have been detected.
Accordingly, management believes that the financial statements included in this
report fairly present in all material respects our financial condition, results
of operations and cash flows for the periods presented.
  Changes
in Internal Control Over Financial Reporting
  In
addition, our management with the participation of our Principal Executive
Officer and Principal Financial Officer have determined that no change in our
internal control over financial reporting occurred during or subsequent to the
quarter ended December 31, 2008 that has materially affected, or is (as that
term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange
Act of 1934) reasonably likely to materially affect, our internal control over
financial reporting.
  PART
II. OTHER INFORMATION
 
 ITEM
1. LEGAL PROCEEDINGS
 
 Management
is not aware of any legal proceedings contemplated by any governmental authority
or any other party involving us or our properties. As of the date of this
Quarterly Report, no director, officer or affiliate is (i) a party adverse to us
in any legal proceeding, or (ii) has an adverse interest to us in any legal
proceedings. Management is not aware of any other legal proceedings pending or
that have been threatened against us or our properties.
 
 ITEM
IA. RISK FACTORS
 
 No report required.
 
 ITEM
2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS
 
 Effective
on April 15, 2009, our Board of Directors approved the execution of the Asset
Purchase Agreement with the Seller. On April 20, 2009, our due diligence was
completed to the satisfaction of both parties and the Asset Purchase Agreement
was consummated. Therefore, on April 20, 2009, the right, title and interest to
the Medical Patents were transferred by the Seller to us and we issued the
250,000 shares of our restricted stock to the Seller as consideration for the
Medical Patents.
  The
issuance of the shares to the Seller was in reliance on Rule 903 of Regulation S
promulgated under the Securities Act of 1933, as amended. The securities issued
in accordance with the Asset Purchase Agreement have not been registered under
the Securities Act or under any state securities laws and may not be offered or
sold without registration with the United States Securities and Exchange
Commission or an applicable exemption from the registration requirements. There
were no finders' fees or commission payable by us upon consummation of the
transaction.
  Table
of Contents
 16
 ITEM
3. DEFAULTS UPON SENIOR SECURITIES
  No report
required.
 
 ITEM
4.SUBMISSIONOF MATTERS TO A VOTE OF SECURITY
HOLDERS
 
 On April
20, 2009, our Board of Directors authorized and approved, subject to shareholder
approval, certain corporate actions, which the Board of Directors deemed to be
in our best interests and our shareholders. Our Board of Directors further
authorized the preparation and circulation of an information statement dated
April 21, 2009 (the “Information Statement”) and a shareholders' consent to
certain shareholders holding a majority of the total issued and outstanding
shares of our common stock (the “Consenting Shareholders”). The Information
Statement was filed with the Securities and Exchange Commission on April 21,
2009.  Management anticipates that the Information Statement will be
first sent or given to our shareholder approximately May 31, 2009.
 
 The
matters upon which action is proposed to be taken is to: (i) approve the
divesture and sale of the our travel related products and assets in accordance
with the terms and provisions of the Agreement with Dirk Holzhauer; (ii) ratify
an amendment (the “Name Change Amendment”) to our Articles of Incorporation, as
amended (the “Articles of Incorporation”) to effectuate a change in our name of
the Corporation (the “Name Change”) to Genova Biotherapeutics Inc.; (iii) ratify
an amendment (the “Change in Capital Structure Amendment”) to our Articles of
Incorporation to amend our authorized capital structure from 65,000,000 shares
of common stock with a par value of $0.001 per share to 1,000,000,000 shares of
common stock with a par value $0.00001 per share; and (iv) to approve the
appointment of the current members of our Board of Directors and to duly
appoint  Hyunho Jin as a member of our Board of Directors to serve
until his successor is duly appointed.
 
 The above
actions were approved by our Board of Directors and the Consenting Holders on
April 20, 2009 and April 21, 2009 respectively. Accordingly, we have
secured the necessary authorization for the above actions.
 
 ITEM
5. OTHERINFORMATION
 
 DEPARTURE
OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN
OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
  On April
10, 2009, Dirk Holzhauer, our sole director, appointed Mr. Aaron Whiteman to
join the Board to fill a vacancy created by the resignation, in September 2008
of the only other member of the Board of Directors. Mr. Whiteman accepted the
appointment on April 10, 2009.
 
 On April
13, 2009, our Board of Directors appointed Mr. Aaron Whiteman as our
President/Chief Executive Officer and Treasurer/Chief Financial Officer, Dr.
John Savin as our Vice President and Mr. Hyunho Jin as our Secretary. Mr.
Whiteman, Dr. Savin, and Mr. Jin all accepted their respective appointments on
April 13, 2009. On April 13, 2009, Mr. Dirk Holzhauer, our incumbent President,
Vice President, Treasurer and Secretary, resigned. The resignation did not
involve any disagreement with us. Mr. Holzhauer will remain one of our
directors.
 
 Table
of Contents
 17
 Therefore,
as a result of the above changes, our officers and directors are as
follows:
  Name
              TitleAaron
      Whiteman
              President/Chief
      Executive Officer, Treasurer/Chief FinancialOfficer and a
    directorJohn
      Savin
              Vice
      PresidentHyunho
      Jin
              SecretaryDirk
      Holzhauer
              Director
  Management
Biographies
 
 Aaron Whiteman.Mr. Aaron
Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from
the London School of Economics.  Most recently, he served as a Vice
President of Reliance Biotech, an Indian medical research company, responsible
for business development and expansion into the European, Middle Eastern,
and African regions.  Prior to that, from May 2002 through May 2007,
Aaron Whiteman was a Vice President of Viranative AB, where he was responsible
for promotion of the company’s products to strategic partners in the Sub-Saharan
region. During his tenure, he successfully secured licensing agreements and
commercial alliances with pharmaceutical giants Pharmacia (Upjohn), Astra
Zeneca, and Glaxo Smith Kline.  He has also held various executive,
board, and advisory positions in the telecommunications industry.
 
 John Savin.Dr. Savin was the
chief executive officer of Physiomics plc, a cancer research and simulation
company he founded in 2001, which was quoted on the London Alternative
Investment Market in 2004. As the chief executive officer, he created a
multi-disciplinary research and development team, raised equity funding,
marketed to major pharmaceutical and biotech companies in Europe and the United
Sates, developedsales pipelines, and
established a global marketing and technology strategic alliance with Bayer AG.
Dr. Savin left Physiomics in 2006 to found Wendover Technology, which provides
consulting services to the biotechnology industry.Wendover Technology
services include investment reports, due diligence on mergers and acquisitions,
strategic planning, project management, and negotiating licensing agreements.
Prior to Physiomics, Dr. Savin was a top-rated investment analyst in the
pharmaceutical and biotech sector in London. He has also worked as a high-level
consultant and has an industry background in international marketing of life
science products and DNA diagnostics. Dr. Savin was awardeda Ph.D. in organic
chemistry from Nottingham University and has an MBA with a distinction in
international business and corporate strategy. He has been a director of various
companies including Biotechconvergence, Wendover Technology, Zetagen and Greig
Middleton & Co.
  Table
of Contents
 18
 Hyunho Jin.Following three
years of compulsory military service, Mr. Hyunho Jin attended Youngjin College
in Seoul, Korea where he received a management diploma. He was hired by the
Hansung office of BTM Services Corp., a management consulting company, where he
was responsible for business development of their regional office. He held that
position for two years before being moved, in May 2000, to the Bohun office,
where he was responsible for international business development, specifically
expansion into South East Asia.
  Dirk Holzhauer.After
completing two years of service in the German army, Mr. Holzhauer attended
Werner-von-Siemenns-Berufskolleg in Cologne where he received a Bachelors Degree
in Business Economics.  This was followed by several business ventures
in Germany before he immigrated to Canada in 1996.  Since then he has
served as an officer and director of both public and private companies in the
United States and Canada, including his position as founding officer, director,
and shareholder of Kinder Travel, Inc. since 2005.  Mr. Holzhauer is a
citizen of Germany and a resident of Canada.
  ITEM
6. EXHIBITSAND REPORTS ON FORM 8-K
  Exhibits:
 
 10.01
                Asset
      Purchase Agreement dated April 20, 2009 between Kinder Travel, Inc. and
      Dirk Holzhauer. (1)10.2
                Asset
      Purchase Agreement dated April 15, 2009 between Kinder Travel, Inc.
      andPhoinos Oxford Lifesciences Limited. (2)31.1
                Certification
      of Chief Executive Officer pursuant to Securities Exchange Act of1934 Rule
      13a-14(a) or 15d-14(a).31.2
                Certification
      of Chief Financial Officer pursuant to Securities Exchange Act of 1934
      Rule
      13a-14(a) or 15d-14(a).32.1
                Certifications
      pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b)
      and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes- Oxley Act of 2002.
  (1)
              Incorporated
      by reference to the exhibit filed with our Current Report on Form 8-K
      filed with the Securities and Exchange Commission on April 21,
      2009.
 
 (2)
              Incorporated
      by reference to the exhibit filed with our Current Report on Form 8-K
      filed with the Securities and Exchange Commission on April 15,
      2009.
 
 Table
of Contents
 19
 SIGNATURES
 
 In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
 KINDER
      TRAVEL, INC.Date:
      May 14, 2009
                By:
                /s/ Aaron
      WhitemanName: Aaron
      WhitemanTitle: President
      andChief
      Executive Officer
  Date:
      May 14 2009
                    By:
                    /s/ Aaron
      WhitemanName:
      Aaron WhitemanTitle:
      Treasurer/Chief Financial Officer
  Table
of Contents
 20